SL Science Holding Limited is a holding company with no substantive business operations of its own, and conducts its business activities through its subsidiary, SL Bio. Unless the context otherwise requires, all references in this section to the “Company,” “SLBT,” “we,” “us,” “our” or “SL Science” refer collectively to SL Science Holding Limited and its subsidiaries.
Preclinical · ActiveModality: cell therapy (engineered T cells armed with bispecific antibodies)
Aliases CD-19 Armed-T
Target CD19
Partnerships CytoArm Co., Ltd (perpetual, irrevocable, royalty-bearing, exclusive license to CD-19 Armed-T patent applications and know-how)
Indications
Blood cancers (CD19)(Preclinical)
Catalysts
— first quarter of 2027
Status note Preclinical. FDA INTERACT meeting written responses received January 6, 2026; company addressing comments and completing nonclinical/manufacturing work; pre-IND meeting planned before filing.
Partnerships Ji Yan Biomedical (JY BioMed; global exclusive licenses for pancreatic and brain cancer GDT cell therapy products; up to $38M milestones, 7%/10% royalties)
Indications
Pancreatic cancer(Preclinical)
Brain cancer(Preclinical)
Catalysts
— third quarter of 2027
Status note Discovery and preclinical phases completed 2024. IND-enabling GLP toxicology studies pending clinical-grade material; orphan-drug designation request declined March 2026 with request for additional nonclinical data.
Per-asset detail extracted from the 20-F filed 2026-06-18. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.